Sodium–Glucose Cotransporter 2 Inhibitor Improves Complications of Lipodystrophy: A Case Report
Authors: Yohei Kawana, Junta Imai, Shojiro Sawada, Tetsuya Yamada, Hideki Katagiri
Journal: Annals of Internal Medicine (2017)

Letters21 March 2017Sodium–Glucose Cotransporter 2 Inhibitor Improves Complications of Lipodystrophy: A Case ReportYohei Kawana, MD, Junta Imai, MD, PhD, Shojiro Sawada, MD, PhD, Tetsuya Yamada, MD, PhD, and Hideki Katagiri, MD, PhDYohei Kawana, MDFrom Tohoku University Hospital, Sendai, Japan., Junta Imai, MD, PhDFrom Tohoku University Hospital, Sendai, Japan., Shojiro Sawada, MD, PhDFrom Tohoku University Hospital, Sendai, Japan., Tetsuya Yamada, MD, PhDFrom Tohoku University Hospital, Sendai, Japan., and Hideki Katagiri, MD, PhDFrom Tohoku University Hospital, Sendai, Japan.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/L16-0372 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: Lipodystrophies are characterized by selective loss of adipose tissue, which leads to fatty liver, insulin resistance, and other complications (1). Lipodystrophies can be acquired or inherited. Infection with HIV may be the best known cause of acquired lipodystrophy, but congenital generalized lipodystrophy is the most severe form. Antidiabetic agents, such as metformin, sulfonylureas, and insulin, often fail to improve glycemic control in patients with lipodystrophy because of the severity of insulin resistance. Leptin improves the complications associated with lipodystrophy (2, 3) but is expensive and requires subcutaneous injections, which are painful because of the lack of subcutaneous adipose tissue ...References1. Garg A. Acquired and inherited lipodystrophies. N Engl J Med. 2004;350:1220-34. [PMID: 15028826] CrossrefMedlineGoogle Scholar2. Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med. 2002;346:570-8. [PMID: 11856796] CrossrefMedlineGoogle Scholar3. Petersen KF, Oral EA, Dufour S, Befroy D, Ariyan C, Yu C, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest. 2002;109:1345-50. [PMID: 12021250] CrossrefMedlineGoogle Scholar4. Patni N, Garg A. Congenital generalized lipodystrophies—new insights into metabolic dysfunction. Nat Rev Endocrinol. 2015;11:522-34. [PMID: 26239609] doi:10.1038/nrendo.2015.123 CrossrefMedlineGoogle Scholar5. Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, et al. Metabolic response to sodium–glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124:499-508. [PMID: 24463454] doi:10.1172/JCI72227 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Tohoku University Hospital, Sendai, Japan.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L16-0372. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byClinical Effects of Sodium-Glucose Transporter Type 2 Inhibitors in Patients With Partial LipodystrophyTreatment Options for Lipodystrophy in ChildrenIdentification of a Novel Mutation in Patients with Type A Insulin Resistance SyndromeFamilial partial lipodystrophy syndromesCase Report: Metreleptin and SGLT2 Inhibitor Combination Therapy Is Effective for Acquired Incomplete LipodystrophySGLT2 inhibitors for genetic and acquired insulin resistance: Considerations for clinical useLong‐term efficacy of the sodium–glucose cotransporter 2 inhibitor, ipragliflozin, in a case of type A insulin resistance syndromeCoexistence of ovarian serous papillary cystadenofibroma and type A insulin resistance syndrome in a 14-year-old girl: A case report Familial Partial Lipodystrophy (FPLD): Recent Insights Fatty liver in lipodystrophy: A review with a focus on therapeutic perspectives of adiponectin and/or leptin replacementClinical characteristics of adolescent cases with Type A insulin resistance syndrome caused by heterozygous mutations in the β-subunit of the insulin receptor ( INSR ) geneTreatment of a case of severe insulin resistance as a result of a PIK3R1 mutation with a sodium-glucose cotransporter 2 inhibitorClinical Characteristics, Phenotype of Lipodystrophy and a Genetic Analysis of Six Diabetic Japanese Women with Familial Partial Lipodystrophy in a Diabetic Outpatient ClinicInsulin 21 March 2017Volume 166, Issue 6Page: 450-451KeywordsAdipose tissueBlood plasmaComputed axial tomographyFatty liverGlucoseHbA1cInsulin resistanceLipodystrophyMusclesSteatosis ePublished: 21 March 2017 Issue Published: 21 March 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...